The presence of an epidermal growth factor receptor (EGFR) mutation is associated with
higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); …

Opinion statement Management of non-small cell lung cancer (NSCLC) with brain
metastasis (BrM) has been revolutionized by identification of molecular subsets that have …

Brain metastasis from non-small cell lung cancer (NSCLC) with epidermal growth factor
receptor (EGFR) mutations is a hot research topic, but also a difficulty in targeted NSCLC …

Brain metastasis is a serious complication of non-small cell lung cancer (NSCLC) affecting
up to 40% of NSCLC patients. A subset of NSCLC tumors has mutations in the epidermal …

Background There are many controversies concerning the best management of epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …

Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …

Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …

Simple Summary Brain metastasis is a factor of a poor prognosis in patients with non-small-
cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …

Results: Epidermal growth factor receptor tyrosine kinase inhibitor monotherapy patients
had better performance status (PS), fewer CNS symptoms, and significantly fewer brain …